Search results
Investor contacts Jenna Cohen Vice President and Head, Investor Relations 857-209-3147 Cassie Saitow Associate Director, Investor Relations 617.909.3127 ir@blueprintmedicines.com Media contact Andrew Law Director, Portfolio Communications media@blueprintmedicines.com 617.844.8205
- Events and Presentations
Investor contacts Jenna Cohen Vice President and Head,...
- Recent News
Except as required by law, Blueprint Medicines expressly...
- SEC Filings
SEC Filings - Overview | Blueprint Medicines Corp.
- Corporate governance
Corporate governance - Overview | Blueprint Medicines Corp.
- Corporate responsibility
The Women’s Edge, a non-profit dedicated to advancing women...
- Analyst coverage
Analyst coverage - Overview | Blueprint Medicines Corp.
- Investor FAQs
Investor contacts Jenna Cohen Vice President and Head,...
- Events and Presentations
May 2, 2015 · Investor contacts Jenna Cohen Vice President and Head, Investor Relations 857-209-3147 Cassie Saitow Associate Director, Investor Relations 617.909.3127 ir@blueprintmedicines.com Media contact Andrew Law Director, Portfolio Communications media@blueprintmedicines.com 617.844.8205
Jan 8, 2024 · Investor contacts Jenna Cohen Vice President and Head, Investor Relations 857-209-3147 Cassie Saitow Associate Director, Investor Relations 617.909.3127 ir@blueprintmedicines.com Media contact Andrew Law Director, Portfolio Communications media@blueprintmedicines.com 617.844.8205
May 4, 2023 · Blueprint Medicines recorded revenues of $62.7 million in the first quarter of 2022, including $23.8 million of net product revenues from sales of AYVAKIT/AYVAKIT and $38.9 million in collaboration revenues. Cost of Sales: Cost of sales was $3.2 million for the first quarter of 2023, as compared to $5.1 million for the first quarter of 2022.
Sep 30, 2021 · BLU-852 is the first development candidate nominated under Blueprint Medicines' cancer immunotherapy collaboration with Roche. Third Quarter 2021 Financial Results. Revenues: Revenues were $24.2 million for the third quarter of 2021, including $17.3 million of net product revenues from sales of AYVAKIT/AYVAKYT and $6.9 million in collaboration ...
The Investor Relations website contains information about Blueprint Medicines Corp.'s business for stockholders, potential investors, and financial analysts.
People also ask
How did blueprint medicines perform in the first quarter of 2022?
What is blueprint medicine's 2024 corporate strategy?
What makes blueprint medicines a great biopharmaceutical company?
Why is blueprint medicines discontinuing investment in specific programs?
Feb 15, 2024 · Blueprint Medicines Corporation. Feb 15, 2024, 07:00 ET. -- Achieved $204.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter ...
